Indivior PharmaceuticalsINDV -1.92%77 Buyback Yield % is 2.58 as of Jul. 01, 2026, which is 100% above its 10-year median of 1.29. GuruFocus rates INDV with a GF Score™ of 77/100 and a GF Value™ of $22.97 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 293 Drug Manufacturers companies, Indivior Pharmaceuticals ranks better than 92.49% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INDV vs KNSA, AMRX, RGC: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indivior Pharmaceuticals Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Indivior Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indivior Pharmaceuticals (INDV) has a Buyback Yield % of 2.58 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Indivior Pharmaceuticals and its competitors. This is 100% above median its historical median of 1.29. According to the industry distribution chart, Indivior Pharmaceuticals ranks #22 out of 293 companies in the Drug Manufacturers industry, placing it in the top 7.5%.
Is Indivior Pharmaceuticals' Buyback Yield % too high?
Indivior Pharmaceuticals' current Buyback Yield % of 2.58 is 100% above median its 10-year median of 1.29. Based on the distribution chart, Indivior Pharmaceuticals ranks #22 out of 293 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Indivior Pharmaceuticals has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Buyback Yield % compare to KNSA and AMRX?
According to the Drug Manufacturers industry distribution chart, Indivior Pharmaceuticals ranks #22 out of 293 companies for Buyback Yield %. This places Indivior Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Indivior Pharmaceuticals and its competitors. Indivior Pharmaceuticals's current Buyback Yield % is 2.58, which is 100% above median its own 10-year median of 1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.97, compared to a current price of $40.25 — trading 75.2% above its estimated fair value. The current Buyback Yield % is 2.58, which is 100% above median its 10-year median of 1.29. Indivior Pharmaceuticals' overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current Buyback Yield % is 2.58 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?
Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued.
The current stock price of $40.25 is trading 75.2% above its estimated GF Value™ of $22.97.
GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for INDV:
Buyback Yield %: 2.58 (100% above median its 10-year median of 1.29)
GF Value™: $22.97 vs. price of $40.25 (75.2% above fair value)
No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
77GF Score
Get the complete analysis for INDV
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INDV has been successfully added to your 
